NCAPH2

Across TCGA pan-cancer cohorts, NCAPH2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NCAPH2 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NCAPH2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NCAPH2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where NCAPH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.224	0.797	<.001	66	view →
LSCC	OS	Median	II,III,IV	0.890	0.595	.008	13	view →
LUAD	OS	Quartile	II,III,IV	0.387	0.759	.031	4	view →
CCRCC	DFS	Median	IV	0.156	0.961	.038	3	view →
HNSC	DFS	Median	All	0.561	0.731	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NCAPH2–PDAC (DFS)

Open the PDAC breakdown →